Asthma-COPD Overlap with Cardiometabolic Syndrome: Navigating Complex Pathophysiology and Therapeutic Challenges in Critical Care

Dr Neeraj manikath , claude.ai

Abstract

Background: Asthma-COPD overlap (ACO) represents a complex phenotype affecting 15-20% of patients with obstructive airway disease. When combined with cardiometabolic syndrome (CMS), these patients present unique therapeutic challenges, particularly in critical care settings where cardiovascular safety and metabolic stability are paramount.

Objectives: To provide evidence-based recommendations for managing ACO patients with CMS, focusing on inhaled therapy optimization, steroid-induced metabolic complications, and the integration of non-pharmacological interventions.

Methods: Comprehensive literature review of PubMed, Cochrane Library, and major respiratory/critical care databases from 2015-2024, focusing on ACO-CMS interactions, therapeutic safety profiles, and outcome data.

Conclusions: ACO-CMS patients require individualized, multidisciplinary management with careful consideration of drug interactions, metabolic monitoring, and aggressive non-pharmacological interventions to optimize outcomes while minimizing iatrogenic complications.

Keywords: Asthma-COPD overlap, cardiometabolic syndrome, inhaled therapy, corticosteroids, pulmonary rehabilitation

Introduction

Asthma-COPD overlap (ACO) represents a distinct clinical phenotype characterized by persistent airflow limitation with features of both asthma and COPD¹. The prevalence of ACO ranges from 15-20% among patients with obstructive airway disease, with increasing recognition of its association with worse clinical outcomes, more frequent exacerbations, and higher healthcare utilization compared to either condition alone²,³.

Cardiometabolic syndrome (CMS), defined by the clustering of insulin resistance, dyslipidemia, hypertension, and central obesity, affects approximately 40% of patients with chronic respiratory diseases⁴. The intersection of ACO and CMS creates a complex pathophysiological milieu involving chronic systemic inflammation, autonomic dysfunction, and shared risk factors that significantly complicate therapeutic decision-making in critical care settings⁵.

Clinical Pearl: ACO patients with CMS have a 2.5-fold higher risk of cardiovascular events and 40% increased mortality compared to those with ACO alone. Early identification and aggressive management of both conditions is crucial⁶.

Pathophysiological Mechanisms

Inflammatory Cross-Talk

The pathophysiology of ACO-CMS involves complex inflammatory networks. Chronic airway inflammation in ACO is characterized by mixed Th2/Th17 responses with increased IL-4, IL-5, IL-13, and IL-17 production⁷. Simultaneously, CMS perpetuates systemic inflammation through adipokine dysregulation, including elevated leptin, reduced adiponectin, and increased TNF-α and IL-6⁸.

This inflammatory milieu creates several key clinical consequences:

Enhanced oxidative stress leading to accelerated lung function decline
Increased insulin resistance through inflammatory cytokine interference with insulin signaling
Endothelial dysfunction promoting both pulmonary vascular disease and systemic atherosclerosis
Sympathetic nervous system activation contributing to both bronchial hyperresponsiveness and metabolic dysfunction⁹

Shared Pathways

Recent genomic studies have identified common pathways linking ACO and CMS, including:

mTOR signaling: Overactivation contributes to both airway remodeling and metabolic dysfunction¹⁰
NF-κB pathway: Central to both chronic airway inflammation and insulin resistance¹¹
PPAR-γ dysfunction: Links adipogenesis, inflammation, and airway remodeling¹²

Oyster Alert: Beware of the "obesity paradox" in ACO-CMS patients. While obesity worsens metabolic parameters, some studies suggest better short-term survival in obese COPD patients, possibly due to nutritional reserves during acute exacerbations¹³.

Optimizing Inhaled Therapy with Cardiovascular Safety

Beta-2 Agonist Considerations

Long-acting beta-2 agonists (LABAs) remain cornerstone therapy for ACO, but cardiovascular safety concerns are amplified in CMS patients due to pre-existing cardiovascular risk factors¹⁴.

Cardiovascular Risk Stratification:

Low risk: Normal ECG, no known CAD, controlled hypertension
Moderate risk: Controlled CAD, diabetes without complications, mild left ventricular dysfunction
High risk: Recent MI, unstable angina, severe heart failure, uncontrolled arrhythmias¹⁵

LABA Selection Strategy

For Low-Moderate CV Risk:

Formoterol: Rapid onset (2-3 minutes), suitable for rescue use in ACO patients
Salmeterol: Longer onset but excellent duration, good for maintenance therapy
Indacaterol: Once-daily dosing improves compliance, minimal CV effects in stable patients¹⁶

For High CV Risk:

Consider avoiding high-dose SABAs
Prefer ICS/LABA combinations with proven CV safety profiles
Vilanterol/Fluticasone furoate: Demonstrated CV safety in large RCTs¹⁷

Critical Care Hack: In mechanically ventilated ACO-CMS patients, nebulized bronchodilators can cause significant tachycardia. Consider MDI with spacer delivery through the ventilator circuit to reduce systemic absorption¹⁸.

Long-Acting Muscarinic Antagonists (LAMAs)

LAMAs offer excellent bronchodilation with minimal cardiovascular effects, making them attractive in CMS patients¹⁹. However, anticholinergic effects may worsen gastric emptying in diabetic patients.

LAMA Selection:

Tiotropium: Extensive safety data, once-daily dosing
Glycopyrronium: Rapid onset, good for symptomatic patients
Umeclidinium: Minimal anticholinergic side effects²⁰

Triple Therapy Considerations

Triple therapy (ICS/LABA/LAMA) is often required in ACO patients but raises concerns about steroid-related metabolic effects²¹.

Evidence-Based Triple Combinations:

Fluticasone furoate/Vilanterol/Umeclidinium: IMPACT trial showed 15% reduction in moderate-severe exacerbations²²
Beclomethasone/Formoterol/Glycopyrronium: TRILOGY study demonstrated non-inferiority to dual therapy with improved lung function²³

Monitoring Requirements for Triple Therapy in CMS:

Monthly blood glucose monitoring for first 3 months
Quarterly HbA1c assessment
Annual bone density screening
Regular blood pressure monitoring²⁴

Steroid-Induced Metabolic Derangements

Systemic vs. Inhaled Corticosteroid Effects

While inhaled corticosteroids (ICS) have lower systemic bioavailability than oral preparations, significant metabolic effects can occur, particularly with high-dose formulations and in patients with pre-existing metabolic dysfunction²⁵.

Glucose Metabolism

Mechanisms of Steroid-Induced Hyperglycemia:

Increased hepatic gluconeogenesis
Peripheral insulin resistance
Enhanced lipolysis with increased substrate availability
Suppression of glucose uptake in peripheral tissues²⁶

High-Risk ICS Formulations for Glucose Dysregulation:

Fluticasone propionate >500 mcg/day
Budesonide >800 mcg/day
Ciclesonide appears to have lowest glucose impact due to lung-specific activation²⁷

Management Strategies:

Dose optimization: Use lowest effective ICS dose
Formulation selection: Consider ciclesonide or mometasone for high-risk patients
Monitoring protocol: Check fasting glucose monthly for first 3 months, then quarterly
Antidiabetic adjustment: May need 10-30% increase in insulin or oral hypoglycemic doses²⁸

Lipid Metabolism

ICS can worsen dyslipidemia through multiple mechanisms:

Increased VLDL production
Reduced lipoprotein lipase activity
Enhanced cholesterol synthesis²⁹

Clinical Hack: Consider adding ezetimibe rather than increasing statin dose in ACO-CMS patients on high-dose ICS, as statins may have anti-inflammatory benefits for airways³⁰.

Bone Metabolism

Bone loss risk is particularly concerning in ACO-CMS patients due to:

Direct corticosteroid effects on osteoblast function
Vitamin D deficiency common in respiratory patients
Reduced physical activity
Chronic inflammation effects on bone remodeling³¹

Bone Protection Protocol:

Baseline DEXA scan for patients requiring long-term ICS
Calcium 1000-1200 mg daily + Vitamin D 800-1000 IU
Consider bisphosphonates if T-score <-1.5 with additional risk factors
Weight-bearing exercise as tolerated³²

Role of Non-Pharmacological Measures

Pulmonary Rehabilitation

Pulmonary rehabilitation (PR) represents a cornerstone intervention for ACO-CMS patients, addressing both respiratory and cardiovascular fitness while potentially improving metabolic parameters³³.

PR Benefits in ACO-CMS:

50-100 meter improvement in 6-minute walk distance
15-20% reduction in dyspnea scores
25% reduction in healthcare utilization
Improved insulin sensitivity and glucose control³⁴

Tailored PR Components:

Exercise Training:
- Aerobic exercise: 30-45 minutes, 3-5 days/week at 60-80% maximum heart rate
- Resistance training: 2-3 sessions/week targeting major muscle groups
- Flexibility and balance training to prevent falls³⁵
Education Components:
- Disease self-management
- Nutrition counseling
- Medication adherence
- Exacerbation recognition and management³⁶

Critical Care Pearl: Early mobilization and breathing exercises in ICU settings can reduce mechanical ventilation duration by 1-2 days in ACO exacerbations. Begin passive ROM on day 1, progress to active exercises as sedation allows³⁷.

Weight Management

Weight loss in ACO-CMS patients provides multisystem benefits:

5-10% weight loss improves lung function by 100-200 mL FEV1
Reduces insulin resistance and improves glycemic control
Decreases cardiovascular risk factors
May reduce exacerbation frequency³⁸

Evidence-Based Weight Loss Strategies:

Caloric Restriction: 500-750 kcal/day deficit targeting 1-2 lbs/week loss
Macronutrient Distribution:
- Protein: 25-30% (1.2-1.6 g/kg to preserve lean mass)
- Carbohydrates: 40-45% (emphasize low glycemic index)
- Fats: 25-30% (emphasize omega-3 fatty acids)³⁹
Pharmacological Support:
- GLP-1 agonists: May improve both glycemic control and weight loss while potentially having anti-inflammatory effects
- Orlistat: Can be used cautiously with fat-soluble vitamin supplementation⁴⁰

Oyster Alert: Rapid weight loss (>2 lbs/week) in COPD patients can lead to muscle wasting and respiratory muscle weakness. Monitor body composition, not just weight⁴¹.

Sleep Optimization

Sleep disorders are highly prevalent in ACO-CMS patients, with obstructive sleep apnea (OSA) present in 60-70% of cases⁴².

Sleep Assessment and Management:

Screen with STOP-BANG questionnaire
Overnight polysomnography for moderate-high risk patients
CPAP therapy improves both respiratory and metabolic outcomes
Target 7-8 hours of quality sleep nightly⁴³

Monitoring and Follow-Up Protocols

Laboratory Monitoring Schedule

Baseline Assessment:

Complete metabolic panel, HbA1c, lipid profile
Inflammatory markers (CRP, fibrinogen)
Vitamin D, B12 levels
Thyroid function tests⁴⁴

Follow-Up Schedule:

Months 1-3: Monthly glucose, quarterly HbA1c
Months 3-12: Quarterly comprehensive metabolic panel
Annually: Lipid profile, inflammatory markers, bone density⁴⁵

Clinical Monitoring

Pulmonary Function:

Spirometry every 3-6 months
Peak flow monitoring for asthmatic component
Fractional exhaled nitric oxide (FeNO) to guide ICS therapy⁴⁶

Cardiovascular Monitoring:

Blood pressure at each visit
ECG annually or with symptoms
Echocardiogram if clinical heart failure suspected
Ankle-brachial index annually⁴⁷

Emergency and Critical Care Considerations

Acute Exacerbation Management

ACO-CMS patients require modified approaches during acute exacerbations due to cardiovascular comorbidities⁴⁸.

Modified Corticosteroid Protocol:

Standard dose: Prednisolone 40mg daily x 5 days
CMS modification: Monitor glucose q6h, sliding scale insulin PRN
Diabetes patients: Consider IV hydrocortisone 100mg q8h with endocrine consultation
Heart failure patients: Monitor fluid balance closely⁴⁹

Bronchodilator Modifications:

Limit nebulized albuterol to q4h in cardiac patients
Consider ipratropium as first-line in tachyarrhythmic patients
IV magnesium sulfate 2g over 20 minutes for severe cases⁵⁰

Mechanical Ventilation Considerations

Ventilator Settings for ACO-CMS:

Mode: Pressure control or PRVC to limit peak pressures
PEEP: 5-8 cmH2O (higher levels may worsen hyperinflation)
I:E ratio: 1:3 or longer to allow complete expiration
Tidal volume: 6-8 mL/kg IBW to prevent volutrauma⁵¹

Critical Care Hack: Use esophageal pressure monitoring to optimize PEEP in obese ACO patients. Chest wall compliance is often reduced, requiring higher PEEP than anticipated⁵².

Special Populations

Elderly Patients (>65 years)

Elderly ACO-CMS patients require particular attention to:

Polypharmacy interactions
Increased fall risk with bronchodilators
Cognitive effects of hypoxemia and medications
Frailty assessment and sarcopenia screening⁵³

Pregnancy

Pregnancy in ACO-CMS patients requires multidisciplinary care:

Preferred medications: Budesonide (Category B), albuterol
Avoid: Oral corticosteroids if possible
Monitor for gestational diabetes and preeclampsia
Maintain optimal asthma control to prevent fetal hypoxia⁵⁴

Future Directions and Emerging Therapies

Biologics in ACO-CMS

Emerging evidence supports biologic therapy in selected ACO patients:

Anti-IL-5 therapy: Mepolizumab reduces exacerbations in eosinophilic ACO
Anti-IL-4/IL-13: Dupilumab shows promise in Th2-high ACO patients
Anti-TSLP: Tezepelumab under investigation for broader ACO phenotypes⁵⁵

Selection Criteria for Biologics:

Blood eosinophils >150 cells/μL (anti-IL-5)
Elevated FeNO >25 ppb (anti-IL-4/IL-13)
≥2 exacerbations/year despite optimal therapy⁵⁶

Precision Medicine Approaches

Future management will likely incorporate:

Genetic testing for medication metabolism
Inflammatory phenotyping to guide therapy
Digital biomarkers from wearable devices
AI-assisted treatment optimization⁵⁷

Clinical Practice Guidelines and Recommendations

Treatment Algorithm

Step 1: Confirm ACO diagnosis with spirometry, reversibility testing, and FeNO Step 2: Assess cardiovascular risk and metabolic status Step 3: Initiate ICS/LABA combination based on risk profile Step 4: Add LAMA if symptoms persist (triple therapy) Step 5: Consider biologics for frequent exacerbators Step 6: Implement comprehensive non-pharmacological program⁵⁸

Quality Metrics

Process Measures:

Appropriate inhaler technique assessment
Annual influenza and pneumococcal vaccination
Smoking cessation counseling
Pulmonary rehabilitation referral⁵⁹

Outcome Measures:

Exacerbation rate reduction
Improvement in quality of life scores
Glycemic control achievement
Cardiovascular risk factor optimization⁶⁰

Pearls and Pitfalls Summary

Pearls:

Early integration: Address respiratory and metabolic components simultaneously from diagnosis
Individualized ICS dosing: Use lowest effective dose with high-potency, low-bioavailability formulations when possible
Cardiovascular monitoring: Regular ECG and blood pressure monitoring in all patients on LABA therapy
Weight-bearing exercise: Essential for bone health in patients requiring chronic corticosteroids
Sleep assessment: Screen all patients for OSA as treatment improves both respiratory and metabolic outcomes

Pitfalls to Avoid:

Steroid over-reliance: Avoid prolonged oral corticosteroids; optimize inhaled therapy instead
Ignoring drug interactions: Beta-blockers and bronchodilators require careful balance
Undertreating cardiovascular risk: ACO patients have 2-fold higher CV mortality
Neglecting nutrition: Both under- and over-nutrition worsen outcomes
Delayed rehabilitation: Early PR referral improves long-term outcomes

Conclusion

Managing ACO with cardiometabolic syndrome requires a comprehensive, individualized approach that balances respiratory symptom control with cardiovascular safety and metabolic stability. Success depends on careful medication selection, aggressive monitoring for drug-related complications, and early implementation of non-pharmacological interventions. As our understanding of the complex pathophysiology continues to evolve, precision medicine approaches and novel therapeutic targets offer hope for improved outcomes in this challenging patient population.

The critical care physician must remain vigilant for the subtle interactions between respiratory medications and metabolic function while maintaining a low threshold for specialist consultation in complex cases. Regular reassessment and treatment optimization remain essential for achieving the best possible outcomes in these multimorbid patients.

References

Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64(8):728-735.
Rhee CK, Yoon HK, Yoo KH, et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma. COPD. 2014;11(2):163-170.
Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127.
Marquis K, Maltais F, Duguay V, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2005;25(4):226-232.
Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728-735.
Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524.
Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):758-766.
Forno E, Lescher R, Strunk R, et al. Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol. 2011;127(3):741-749.
Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16-27.
Haughney J, Aubier M, Jorgensen L, et al. Integrating guideline-defined asthma-COPD overlap with treatment response in primary care. NPJ Prim Care Respir Med. 2021;31(1):35.
Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 2006;28(1):219-242.
Belvisi MG, Hele DJ. Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest. 2008;134(1):152-157.
Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82(1):53-59.
Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309-2321.
Suissa S, Hemmelgarn B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1598-1602.
Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155-162.
Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817-1826.
Dhand R, Tobin MJ. Inhaled bronchodilator therapy in mechanically ventilated patients. Am J Respir Crit Care Med. 1997;156(1):3-10.
Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137(1):20-30.
Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 study. Int J Chron Obstruct Pulmon Dis. 2012;7:503-513.
Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671-1680.
Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438-446.
Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963-973.
Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001-1006.
Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367(10):904-912.
Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17(9):717-720.
Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042-1050.
Dendukuri N, Blais L, LeLorier J. Inhaled corticosteroids and the risk of diabetes among the elderly. Br J Clin Pharmacol. 2002;54(1):59-64.
Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001-1006.
Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554-2560.
Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345(13):941-947.
Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515-1526.
Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13-64.
Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(4):CD003793.
Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173(12):1390-1413.
Bolton CE, Bevan-Smith EF, Blakey JD, et al. British Thoracic Society guideline on pulmonary rehabilitation in adults. Thorax. 2013;68 Suppl 2:ii1-30.
Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009;373(9678):1874-1882.
Steuten LM, Creutzberg EC, Vrijhoef HJ, Wouters EF. COPD as a multicomponent disease: inventory of dyspnoea, underweight, depression and fatigue. Prim Care Respir J. 2006;15(2):84-91.
Schols AM, Ferreira IM, Franssen FM, et al. Nutritional assessment and therapy in COPD: a European Respiratory Society statement. Eur Respir J. 2014;44(6):1504-1520.
Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58(5):399-404.
Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1791-1797.
Sharma B, Feinsilver S, Owens RL, et al. Obstructive airway disease and obstructive sleep apnea: effect of pulmonary function. Lung. 2011;189(1):37-41.
Machado MC, Vollmer WM, Togeiro SM, et al. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J. 2010;35(1):132-137.
Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165-1185.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2023 Report.
Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-615.
Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631-639.
Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340(25):1941-1947.
Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223-2231.
Rowe BH, Bretzlaff JA, Bourdon C, et al. Intravenous magnesium sulfate treatment for acute asthma in the emergency department: a systematic review of the literature. Ann Emerg Med. 2000;36(3):181-190.
Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med. 2013;369(22):2126-2136.
Talmor D, Sarge T, Malhotra A, et al. Mechanical ventilation guided by esophageal pressure in acute lung injury. N Engl J Med. 2008;359(20):2095-2104.
Lahousse L, Ziere G, Verlinden VJ, et al. Risk of frailty in elderly with COPD: a population-based study. J Gerontol A Biol Sci Med Sci. 2016;71

Saturday, September 27, 2025